Quick Answer
Teladoc Health, Inc. reported Total Revenue of $2.53 billion for fiscal year 2025.
Teladoc Health, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.53B -1.5% |
$2.57B -1.3% |
$2.60B +8.1% |
$2.41B +18.4% |
$2.03B +85.8% |
$1.09B |
| Revenue (ASC 606) | $2.53B -1.5% |
$2.57B -1.3% |
$2.60B +8.1% |
$2.41B +18.4% |
$2.03B +85.8% |
$1.09B |
| Net Income | -$200.32M +80.0% |
-$1.00B -354.4% |
-$220.37M +98.4% |
-$13.66B -3085.6% |
-$428.79M +11.6% |
-$485.14M -390.7% |
| Diluted EPS | -$1.14 +80.6% |
-$5.87 -338.1% |
-$1.34 +98.4% |
-$84.60 -2998.9% |
-$2.73 +49.1% |
-$5.36 -288.4% |
| Total Assets | $2.86B -18.7% |
$3.52B -19.9% |
$4.39B +1.1% |
$4.35B -75.5% |
$17.73B -0.1% |
$17.76B +1007.7% |
| Cash and Equivalents | $781.08M -39.8% |
$1.30B +15.5% |
$1.12B +22.4% |
$918.18M +2.8% |
$893.48M +21.8% |
$733.32M +42.6% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $1.39B -7.1% |
$1.49B -35.9% |
$2.33B +0.8% |
$2.31B -85.6% |
$16.05B +1.0% |
$15.88B +1466.4% |
| R&D Expense | $277.92M -9.6% |
$307.27M -11.8% |
$348.52M +4.5% |
$333.63M +7.0% |
$311.88M +89.1% |
$164.94M +155.2% |
| Operating Income | -$262.95M +74.2% |
-$1.02B -310.7% |
-$248.55M +98.2% |
-$13.65B -5039.9% |
-$265.63M +47.5% |
-$506.42M -529.5% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 178.32M +2.8% |
173.41M +4.0% |
166.66M +2.3% |
162.84M +1.5% |
160.47M +6.8% |
150.28M +106.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $626.44M | -2.2% | -0.9% |
| Revenue (ASC 606) | September 30, 2025 | $626.44M | -2.2% | -0.9% |
| Net Income | September 30, 2025 | -$49.51M | -48.8% | -51.6% |
| Diluted EPS | September 30, 2025 | -$0.28 | -47.4% | -47.4% |
| Total Assets | September 30, 2025 | $2.88B | -18.4% | -0.5% |
| Cash and Equivalents | September 30, 2025 | $726.25M | -41.6% | +6.9% |
| Long-Term Debt | March 31, 2017 | $42.43M | +70.0% | +0.0% |
| Stockholders Equity | September 30, 2025 | $1.39B | -7.7% | -2.1% |
| R&D Expense | September 30, 2025 | $67.57M | -6.6% | -1.8% |
| Operating Income | September 30, 2025 | -$51.96M | -17.0% | +4.5% |
| Gross Profit | March 31, 2019 | $83.90M | +33.6% | +9.2% |
| Shares Outstanding | September 30, 2025 | 177.35M | +3.1% | +0.4% |
- Teladoc Health, Inc. reported Total Revenue of $2.53 billion for fiscal year 2025.
- Teladoc Health, Inc. showed a decrease of -1.5% in Total Revenue compared to the prior fiscal year.
- Teladoc Health, Inc. reported Revenue (ASC 606) of $2.53 billion for fiscal year 2025.
- Teladoc Health, Inc. showed a decrease of -1.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Teladoc Health, Inc. reported Net Income of -$200.32 million for fiscal year 2025.
- Teladoc Health, Inc. showed an increase of +80.0% in Net Income compared to the prior fiscal year.
- Teladoc Health, Inc. reported Diluted EPS of $1.14 per share (loss) for fiscal year 2025.
- Teladoc Health, Inc. showed an increase of +80.6% in Diluted EPS compared to the prior fiscal year.
- Teladoc Health, Inc. reported Total Assets of $2.86 billion for fiscal year 2025.
- Teladoc Health, Inc. showed a decrease of -18.7% in Total Assets compared to the prior fiscal year.
- Teladoc Health, Inc. reported Cash and Equivalents of $781.08 million for fiscal year 2025.
- Teladoc Health, Inc. showed a decrease of -39.8% in Cash and Equivalents compared to the prior fiscal year.
- Teladoc Health, Inc. reported Long-Term Debt of $42.42 million for fiscal year 2016.
- Teladoc Health, Inc. showed an increase of +68.2% in Long-Term Debt compared to the prior fiscal year.
- Teladoc Health, Inc. reported Stockholders Equity of $1.39 billion for fiscal year 2025.
- Teladoc Health, Inc. showed a decrease of -7.1% in Stockholders Equity compared to the prior fiscal year.
- Teladoc Health, Inc. reported R&D Expense of $277.92 million for fiscal year 2025.
- Teladoc Health, Inc. showed a decrease of -9.6% in R&D Expense compared to the prior fiscal year.
- Teladoc Health, Inc. reported Operating Income of -$262.95 million for fiscal year 2025.
- Teladoc Health, Inc. showed an increase of +74.2% in Operating Income compared to the prior fiscal year.
- Teladoc Health, Inc. reported Gross Profit of $289.17 million for fiscal year 2018.
- Teladoc Health, Inc. showed an increase of +68.5% in Gross Profit compared to the prior fiscal year.
- Teladoc Health, Inc. reported Shares Outstanding of 178.32 million shares for fiscal year 2025.
- Teladoc Health, Inc. showed an increase of +2.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: